(Q43509817)

English

Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit

scientific article published on 19 September 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

metabolic syndrome

1 reference

based on heuristic

inferred from title

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

Annamaria Morelli

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

11

object named as

Mario Maggi

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

author name string

Paolo Comeglio

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sandra Filippi

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Erica Sarchielli

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Linda Vignozzi

5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Elena Maneschi

6

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Ilaria Cellai

7

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Gabriella B Vannelli

10

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

19 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

73

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

428-441

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Abdominal obesity and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Lower urinary tract symptoms, obesity and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

The correlation between metabolic syndrome and prostatic diseases

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Farnesoid X receptor activation improves erectile dysfunction in models of metabolic syndrome and diabetes

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Estrogens, but not androgens, regulate expression and functional activity of oxytocin receptor in rabbit epididymis

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Characterization and functional role of androgen-dependent PDE5 activity in the bladder

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

The effects of aging on the molecular and cellular composition of the prostate microenvironment

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Differentiation of effector CD4 T cell populations (*)

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Testosterone and metabolic syndrome: a meta-analysis study

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Phosphodiesterase type 5 (PDE5) in the adipocyte: a novel player in fat metabolism?

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Reduced vascular nitric oxide-cGMP signaling contributes to adipose tissue inflammation during high-fat feeding.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22584

21 January 2018

Identifiers

10.1002/PROS.22584

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43509817&oldid=1990226094"